An illustration showing two pairs of hands, where one of them holds a kidney that seems to be offered to the other.

Targeting key cells within the immune system of kidney transplant recipients shows promise for extending the lifespan of the organ.

Credit: iStock/CreativeDesignArt

Targeting T cells to fight chronic transplant rejection

Certain T cells may offer potential therapeutic targets for prolonging organ survival in kidney transplant recipients.
Alejandra Manjarrez headshot
| 4 min read
Register for free to listen to this article
Listen with Speechify
0:00
4:00

Patients who receive an organ transplant often experience more than the restoration of their health; they can enjoy their favorite foods once again or even run marathons. Yet, despite an initially successful transplant, several factors may eventually result in chronic rejection, leading to organ failure (1).

A photo of two researchers in white coats, one of them seated and the other standing behind. Both are looking at a computer displaying an image of kidney tissue stained with different colors.
Martin Oberbarnscheidt and his colleague Khodor Abou-Daya analyze immunofluorescence staining of renal allograft tissue.
Credit: University of Pittsburgh

The transplant recipient’s immune system is one of the key players in the long-term success of the intervention. In particular, a subset of the recipient’s memory T cells that form in the transplanted organ may contribute to chronic rejection (2). In a recent study published in Science Immunology, researchers explored the factors modulating the activity of these tissue-resident memory T (TRM) cells in a mouse model of kidney transplantation (3). They found that activity of the inflammatory cytokine interleukin-15 (IL-15) is important for these cells’ maintenance. When researchers inhibited IL-15, the new organ survived six months after transplantation, while in most untreated mice, the organ failed after four months.

For Laura Mackay, an immunologist at the University of Melbourne who did not participate in this study, the research showed promise for treatment development. “You can modulate tissue-specific T cells to prevent chronic rejection,” she said. 

Under ordinary circumstances, TRM cells provide tissues with rapid protection against pathogens that they’ve encountered before. “You don't have to wait for that infiltration of circulating T cells to come back into the tissue, which is often too late with a viral infection,” said Mackay. 

In organ transplants, however, the defensive ability of the noncirculating T cells may bring trouble. 

“When we began these studies, we didn’t know if tissue-resident memory T cells would even form in the setting of transplantation,” said Martin Oberbarnscheidt, a transplant immunologist at the University of Pittsburgh and coauthor of the new study. But in 2021, he and his colleagues reported that effector T cells differentiate into TRM cells in transplanted kidneys in mice and that they contributed to allograft rejection (2). 

The next question was how the body maintains these cells in the transplanted organs. “It’s important because once we know what makes them stay in the tissue, maybe we can devise methods to get rid of them,” Oberbarnscheidt noted. 

The team first investigated whether the continuous presence of the antigen itself — those molecules in the donor organ that T cells identify as foreign — is necessary for the maintenance of the TRM cells. Previous studies have yielded mixed results as to whether sustained antigen exposure is necessary for maintaining the activity of these cells in viral infections (4,5), and in the context of allograft tissue, this had never been studied. In their mouse model, Oberbarnscheidt and his colleagues found that the persistent interaction between TRM cells and the antigen within the tissue was indeed required for TRM cell maintenance. 

Since it’s not currently possible to remove the offending antigens from the transplanted organ, the team next investigated what other elements maintain the functionality of these cells within the graft. Their main candidate was IL-15, an inflammatory cytokine essential for maintaining memory T cells and required for TRM cell survival in the context of viral infection (6). To test its role in chronic organ rejection, the researchers treated the transplant recipients with an anti-CD122 antibody, which blocks IL-15 signaling, three times weekly for a period of two weeks. The treatment significantly reduced the number of TRM cells in the transplanted kidney when compared to the number in untreated mice. 

We achieved long-term graft survival without any rejection in mice, and we saw a reduction of these tissue-resident memory T cells in the graft. 
- Martin Oberbarnscheidt, University of Pittsburgh

Extending this antibody treatment for the 182-day study period resulted in a remarkable increase of graft survival. The transplanted kidneys of all six mice that received the anti-CD122 treatment survived six months after transplantation, whereas the researchers only saw such survival extension in one of the seven untreated mice.

The anti-CD122 antibody’s capacity to modulate TRM cells has previously shown favorable outcomes for potentially treating other diseases, for instance, vitiligo (7). However, Mackay noted that for organ rejection, systemic blockade of IL-15 may have downstream consequences. Therefore, this approach requires the development of more TRM-specific therapies, which many researchers are currently working on, she said.

While Oberbarnscheidt acknowledged that further work is needed to assess the potential toxicity and other side effects of the approach, he added that these initial results are encouraging. “What was very promising in using this antibody was that we achieved long-term graft survival without any rejection in mice, and we saw a reduction of these tissue-resident memory T cells in the graft,” he said. If this outcome is mirrored in studies in nonhuman primates and, ultimately, in clinical trials, this strategy could one day be life-changing for transplant recipients in the long term. 

References

  1. Chronic transplantation rejection. StatPearls - NCBI bookshelf at https://www.ncbi.nlm.nih.gov/books/NBK535435/ 
  2. Abou-Daya, K.I. et al. Resident memory T cells form during persistent antigen exposure leading to allograft rejection. Sci Immunol  6, eabc8122 (2021).
  3. Tieu, R. et al. Tissue-resident memory T cell maintenance during antigen persistence requires both cognate antigen and interleukin-15. Sci Immunol  8, eadd8454 (2023). 
  4. Mackay, L.K. et al. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. PNAS  109,  7037–7042 (2012).
  5. Khan, T.N. et al. Local antigen in nonlymphoid tissue promotes resident memory CD8+ T cell formation during viral infection. J Exp Med  213, 951-966 (2016).
  6. Mackay, et al. T-box Transcription Factors Combine with the Cytokines TGF-β and IL-15 to Control Tissue-Resident Memory T Cell Fate. Immunity  43, 1101-11 (2015).
  7. Richmond, J.M. et al. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci Transl Med  18, eaam7710 (2018).

About the Author

  • Alejandra Manjarrez headshot
    Alejandra Manjarrez joined Drug Discovery News as an assistant editor in 2023. She earned her PhD from ETH Zurich, Switzerland, in 2018, and has written for The Scientist, Science, Knowable Magazine, The Atlantic, and others. She is an inveterate reader and dancer, and likes travelling.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

An illustration of three immune cells attacking a cancer cell, representing the mechanism of chimeric antigen receptor-based cell therapy

Cell therapy's next frontiers

As cell therapy evolves rapidly, what advancements are on the horizon? 
An illustration of a human heart on top of a DNA strand

Reversing rejection: gene therapy in modern transplantation

Emerging gene editing approaches pave the way for safer, more successful transplants.
An 3D illustration of protein molecules in different colors

Identifying druggable therapeutic targets

Effective target identification is central to drug discovery, but finding the right drug target is not as simple as it may seem in theory. 
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue